Briefly, the anti-PD-1 antibody camrelizumab functions by blocking the binding of PD-1 on cytotoxic T cells to PD-L1 on tumor cells and consequently inhibit the immune escape of tumor cells. Here, PDCD1 is linked to neoplasm.